Skip to main content
main-content

15.10.2015 | Original Article | Ausgabe 3/2016

Tumor Biology 3/2016

Early downregulation of acute phase proteins after doxorubicin exposition in patients with breast cancer

Zeitschrift:
Tumor Biology > Ausgabe 3/2016
Autoren:
Carolina Panis, Luciana Pizzatti, Aedra Carla Bufalo, Ana Cristina Herrera, Vanessa Jacob Victorino, Rubens Cecchini, Eliana Abdelhay
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s13277-015-4203-7) contains supplementary material, which is available to authorized users.

Abstract

Chemotherapy remains the first-choice option for adjuvant therapy in breast cancer. Here, we investigated the impact of the first chemotherapic cycle of doxorubicin on the plasmatic–proteomic profiling of women diagnosed with breast cancer (n = 87). Blood samples were obtained from the same patient before and after doxorubicin infusion (1 h, 60 mg/m2) and processed for label-free LC-MS proteomic screening. A total of 80 proteins were downregulated after chemotherapy. In silico analysis revealed that the main biological process enrolled was inflammation and canonical pathways involving acute phase proteins. TNF-α, IL-1β, IL-12, TGF-β1, clusterin, and gelsolin were chosen as relevant for further validation. All selected targets presented reduced plasmatic levels after treatment. Our results indicate that doxorubicin downregulated acute phase proteins immediately after its infusion. Since such proteins are cancer promoting, its downregulation could support the effectiveness of doxorubicin along treatment.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary Table 1 (XLS 40kb)
13277_2015_4203_MOESM1_ESM.xls
Supplementary Table 2 (XLS 1841kb)
13277_2015_4203_MOESM2_ESM.xls
Supplementary Table 3 (XLS 1981kb)
13277_2015_4203_MOESM3_ESM.xls
Supplementary Table 4 (XLS 58kb)
13277_2015_4203_MOESM4_ESM.xls
Supplementary Table 5 (XLS 57kb)
13277_2015_4203_MOESM5_ESM.xls
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2016

Tumor Biology 3/2016Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.